ClinicalTrials.Veeva

Menu
E

Eastside Research Associates | Redmond, WA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

LY3502970
Orforglipron
LY3298176
Tirzepatide
Retatrutide
LY3985863
PF-07817883
Tempol
EDP-938
MBM-02

Parent organization

This site is a part of Eastside Research Associates

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 21 total trials

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Active, not recruiting
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

This is a Phase 2b, randomized, double-blind, placebo-controlled study of EDP-938 administered orally for the treatment of non-hospitalized adult sub...

Enrolling
RSV Infection
Drug: Placebo
Drug: EDP-938

The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes a...

Active, not recruiting
Type 2 Diabetes
Drug: Semaglutide
Drug: Orforglipron

This study will investigate the efficacy and safety of once daily oral orforglipron in adult participants with obesity or overweight with weight-rela...

Active, not recruiting
Overweight or Obesity
Overweight
Drug: Placebo
Drug: Orforglipron

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo

The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity...

Enrolling
Overweight
Obesity
Drug: Bimagrumab
Drug: Placebo

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and ina...

Enrolling
Diabetes Type 2
Drug: Placebo
Drug: Retatrutide

Assessing precision of i-STAT K test using the IUO i-STAT CG8+ cartridge on the i-STAT 1 Analyzer.

Enrolling
Precision of Potassium (K) Test in Capillary Whole Blood
Diagnostic Test: Fingerstick blood draw

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Chronic Kidney Disease (CKD)
Drug: Retatrutide
Drug: Placebo

Trial sponsors

Lilly logo
Abbott logo
Pfizer logo
Abbott logo
A
Enanta Pharmaceuticals logo
P
P
Roche logo
T

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems